Method for distinguishing normal and transformed cells using G1 kinase inhibitors

Crissman, Harry A; Gadbois, Donna M; Tobey, Robert A; Bradbury, E Morton

Title: Method for distinguishing normal and transformed cells using G1 kinase inhibitors

Abstract

A G.sub.1 phase kinase inhibitor is applied in a low concentration to a population of normal and transformed mammalian cells. The concentration of G.sub.1 phase kinase inhibitor is selected to reversibly arrest normal mammalian cells in the G.sub.1 cell cycle without arresting growth of transformed cells. The transformed cells may then be selectively identified and/or cloned for research or diagnostic purposes. The transformed cells may also be selectively killed by therapeutic agents that do not affect normal cells in the G.sub.1 phase, suggesting that such G.sub.1 phase kinase inhibitors may form an effective adjuvant for use with chemotherapeutic agents in cancer therapy for optimizing the killing dose of chemotherapeutic agents while minimizing undesirable side effects on normal cells.

Inventors:

Crissman, Harry A ^[1]; Gadbois, Donna M ^[1]; Tobey, Robert A ^[1]; Bradbury, E Morton ^[2]

Los Alamos, NM
Santa Fe, NM

Issue Date:: 1993-01-01

Research Org.:: Los Alamos National Lab. (LANL), Los Alamos, NM (United States)

OSTI Identifier:: 868655

Patent Number(s):: 5185260

Assignee:: United States of America as represented by United States (Washington, DC)

Patent Classifications (CPCs):: A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

G - PHYSICS G01 - MEASURING G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES

Show more

A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
A61K31/40 - having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

G - PHYSICS G01 - MEASURING G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
G01N33/5306 - {Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding}

A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
A61K31/55 - having seven-membered rings, e.g. azelastine, pentylenetetrazole

Show less

DOE Contract Number:: W-7405-ENG-36

Resource Type:: Patent

Country of Publication:: United States

Language:: English

Subject:: method; distinguishing; normal; transformed; cells; g1; kinase; inhibitors; phase; inhibitor; applied; concentration; population; mammalian; selected; reversibly; arrest; cell; cycle; arresting; growth; selectively; identified; cloned; diagnostic; purposes; killed; therapeutic; agents; affect; suggesting; form; effective; adjuvant; chemotherapeutic; cancer; therapy; optimizing; killing; dose; minimizing; undesirable; effects; therapeutic agents; normal cells; cancer therapy; cell cycle; mammalian cells; therapeutic agent; phase kinase; diagnostic purposes; kinase inhibitor; /435/424/999/

Citation Formats


                    Crissman, Harry A, Gadbois, Donna M, Tobey, Robert A, and Bradbury, E Morton. Method for distinguishing normal and transformed cells using G1 kinase inhibitors.  United States: N. p., 1993. 
        Web.

Copy to clipboard


                    Crissman, Harry A, Gadbois, Donna M, Tobey, Robert A, & Bradbury, E Morton. Method for distinguishing normal and transformed cells using G1 kinase inhibitors.  United States.

Copy to clipboard


                    Crissman, Harry A, Gadbois, Donna M, Tobey, Robert A, and Bradbury, E Morton. Fri .  
        "Method for distinguishing normal and transformed cells using G1 kinase inhibitors".  United States.  https://www.osti.gov/servlets/purl/868655.

Copy to clipboard


                    
@article{osti_868655,

  title        = {Method for distinguishing normal and transformed cells using G1 kinase inhibitors},

  author       = {Crissman, Harry A and Gadbois, Donna M and Tobey, Robert A and Bradbury, E Morton},

  abstractNote = {A G.sub.1 phase kinase inhibitor is applied in a low concentration to a population of normal and transformed mammalian cells. The concentration of G.sub.1 phase kinase inhibitor is selected to reversibly arrest normal mammalian cells in the G.sub.1 cell cycle without arresting growth of transformed cells. The transformed cells may then be selectively identified and/or cloned for research or diagnostic purposes. The transformed cells may also be selectively killed by therapeutic agents that do not affect normal cells in the G.sub.1 phase, suggesting that such G.sub.1 phase kinase inhibitors may form an effective adjuvant for use with chemotherapeutic agents in cancer therapy for optimizing the killing dose of chemotherapeutic agents while minimizing undesirable side effects on normal cells.},

  doi          = {},

  journal      = {},
number       = ,

  volume       = ,

  place        = {United States},

  year         = {1993},

  month        = {1}

}

Copy to clipboard

Patent:

View Patent

Save / Share:

Export Metadata

Save to My Library

Works referenced in this record:

Staurosporine, a potent protein kinase C inhibitor, fails to inhibit 12-O-tetradecanoylphorbol-13-acetate-caused ornithine decarboxylase induction in isolated mouse epidermal cells
journal, October 1987

Kiyoto, Itsumi; Yamamoto, Satoshi; Aizu, Eriko
Biochemical and Biophysical Research Communications, Vol. 148, Issue 2
https://doi.org/10.1016/0006-291X(87)90938-7

Similar Records in DOE Patents and OSTI.GOV collections:

Method for distinguishing normal and transformed cells using G1 kinase inhibitors

Patent Crissman, H A; Gadbois, D M; Tobey, R A; ...

A G[sub 1] phase kinase inhibitor is applied in a low concentration to a population of normal and transformed mammalian cells. The concentration of G[sub 1] phase kinase inhibitor is selected to reversibly arrest normal mammalian cells in the G[sub 1] cell cycle without arresting growth of transformed cells. The transformed cells may then be selectively identified and/or cloned for research or diagnostic purposes. The transformed cells may also be selectively killed by therapeutic agents that do not affect normal cells in the G[sub 1] phase, suggesting that such G[sub 1] phase kinase inhibitors may form an effective adjuvant formore »« less
Method for distinguishing normal and transformed cells using G1 kinase inhibitors

Patent Application Crissman, H A; Gadbois, D M; Tobey, R A; ...

A G{sub 1} phase kinase inhibitor is applied in a low concentration to a population of normal and transformed mammalian cells. The concentration of G{sub 1} phase kinase inhibitor is selected to reversibly arrest normal mammalian cells in the G{sub 1} cell cycle without arresting growth of transformed cells. The transformed cells may then be selectively identified and/or cloned for research or diagnostic purposes. The transformed cells may also be selectively killed by therapeutic agents that do not affect normal cells in the G{sub 1} phase, suggesting that such G{sub 1} phase kinase inhibitors may form an effective adjuvant formore »« less
Full Text Available
Methods Of Using Chemical Libraries To Search For New Kinase Inhibitors

Patent Gray, Nathanael S. (Berkeley, CA), Schultz, Peter (Oakland, CA), Wodicka, Lisa (Santa Clara, CA), Meijer, Laurent (Roscoff, FR), Lockhart, David J. (Mountain View, CA)

The generation of selective inhibitors for specific protein kinases would provide new tools for analyzing signal transduction pathways and possibly new therapeutic agents. We have invented an approach to the development of selective protein kinase inhibitors based on the unexpected binding mode of 2,6,9-trisubstituted purines to the ATP binding site of human CDK2. The most potent inhibitor, purvalanol B (IC.sub.50 =6 nM), binds with a 30-fold greater affinity than the known CDK2 inhibitor, flavopiridol. The cellular effects of this class of compounds were examined and compared to those of flavopiridol by monitoring changes in mRNA expression levels for all genesmore »« less
Full Text Available
Method for distinguishing multiple targets using time-reversal acoustics

Patent Berryman, James G.

A method for distinguishing multiple targets using time-reversal acoustics. Time-reversal acoustics uses an iterative process to determine the optimum signal for locating a strongly reflecting target in a cluttered environment. An acoustic array sends a signal into a medium, and then receives the returned/reflected signal. This returned/reflected signal is then time-reversed and sent back into the medium again, and again, until the signal being sent and received is no longer changing. At that point, the array has isolated the largest eigenvalue/eigenvector combination and has effectively determined the location of a single target in the medium (the one that is mostmore »« less
Full Text Available
Method for detecting and distinguishing between specific types of environmental radiation using a high pressure ionization chamber with pulse-mode readout

Patent Degtiarenko, Pavel V.

An environmental radiation detector for detecting and distinguishing between all types of environmental radiation, including photons, charged particles, and neutrons. A large volume high pressure ionization chamber (HPIC) includes BF.sub.3 gas at a specific concentration to render the radiation detector sensitive to the reactions of neutron capture in Boron-10 isotope. A pulse-mode readout is connected to the ionization chamber capable of measuring both the height and the width of the pulse. The heavy charged products of the neutron capture reaction deposit significant characteristic energy of the reaction in the immediate vicinity of the reaction in the gas, producing a signalmore »« less
Full Text Available

Similar Records

Title: Method for distinguishing normal and transformed cells using G1 kinase inhibitors

Abstract

Citation Formats

Staurosporine, a potent protein kinase C inhibitor, fails to inhibit 12-O-tetradecanoylphorbol-13-acetate-caused ornithine decarboxylase induction in isolated mouse epidermal cells journal, October 1987

Staurosporine, a potent protein kinase C inhibitor, fails to inhibit 12-O-tetradecanoylphorbol-13-acetate-caused ornithine decarboxylase induction in isolated mouse epidermal cells
journal, October 1987